IL277215B2 - Use of anti-IL-36R antibodies for the treatment of generalized pustular psoriasis - Google Patents
Use of anti-IL-36R antibodies for the treatment of generalized pustular psoriasisInfo
- Publication number
- IL277215B2 IL277215B2 IL277215A IL27721520A IL277215B2 IL 277215 B2 IL277215 B2 IL 277215B2 IL 277215 A IL277215 A IL 277215A IL 27721520 A IL27721520 A IL 27721520A IL 277215 B2 IL277215 B2 IL 277215B2
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- weeks
- dose
- il36r
- administered
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642641P | 2018-03-14 | 2018-03-14 | |
| US201862683720P | 2018-06-12 | 2018-06-12 | |
| US201862699274P | 2018-07-17 | 2018-07-17 | |
| US201862729518P | 2018-09-11 | 2018-09-11 | |
| PCT/US2019/021335 WO2019177888A1 (en) | 2018-03-14 | 2019-03-08 | Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL277215A IL277215A (en) | 2020-10-29 |
| IL277215B1 IL277215B1 (en) | 2025-06-01 |
| IL277215B2 true IL277215B2 (en) | 2025-10-01 |
Family
ID=65904556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL277215A IL277215B2 (en) | 2018-03-14 | 2019-03-08 | Use of anti-IL-36R antibodies for the treatment of generalized pustular psoriasis |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20190284285A1 (https=) |
| EP (1) | EP3765513A1 (https=) |
| JP (2) | JP7404256B2 (https=) |
| KR (1) | KR102768040B1 (https=) |
| CN (1) | CN112272674A (https=) |
| AU (1) | AU2019236105B2 (https=) |
| BR (1) | BR112020016738A2 (https=) |
| CA (1) | CA3093692A1 (https=) |
| CL (1) | CL2020002342A1 (https=) |
| IL (1) | IL277215B2 (https=) |
| MX (1) | MX2020009544A (https=) |
| PH (1) | PH12020551444A1 (https=) |
| WO (1) | WO2019177888A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115925932A (zh) | 2015-04-15 | 2023-04-07 | 安奈普泰斯生物有限公司 | 针对白细胞介素36受体（il-36r）的抗体 |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| BR112020016738A2 (pt) | 2018-03-14 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Uso de anticorpos anti-il-36r para o tratamento de psoríase pustular generalizada |
| AU2019306217B2 (en) | 2018-07-16 | 2024-01-25 | Regeneron Pharmaceuticals, Inc. | Anti-IL36R antibodies |
| TW202037604A (zh) * | 2018-12-27 | 2020-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 治療掌蹠膿疱症之抗il-36r抗體 |
| IL286100B2 (en) | 2019-03-08 | 2024-12-01 | Boehringer Ingelheim Int | Anti-il-36r antibody formulations |
| BR112022026999A2 (pt) * | 2020-07-17 | 2023-01-24 | Boehringer Ingelheim Int | Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas |
| EP4188441A1 (en) * | 2020-07-30 | 2023-06-07 | AnaptysBio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis |
| WO2022026829A1 (en) * | 2020-07-30 | 2022-02-03 | Anaptysbio, Inc. | Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity |
| CN121324513A (zh) * | 2020-09-16 | 2026-01-13 | 上海市皮肤病医院 | 基于代谢组学的泛发性脓疱型银屑病诊断标志物及其应用 |
| EP4221839A1 (en) * | 2020-09-30 | 2023-08-09 | Boehringer Ingelheim International GmbH | Anti-il-36r antibodies for treatment of chronic inflammatory pain |
| CN114907477A (zh) * | 2021-02-08 | 2022-08-16 | 上海普铭生物科技有限公司 | 抗人il-36r抗体及其应用 |
| CA3209006A1 (en) * | 2021-03-04 | 2022-09-09 | Boehringer Ingelheim International Gmbh | Methods for the treatment of gpp |
| EP4305207A2 (en) * | 2021-03-12 | 2024-01-17 | Boehringer Ingelheim International GmbH | Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis |
| JP2024518536A (ja) * | 2021-05-12 | 2024-05-01 | アナプティスバイオ インコーポレイティッド | 抗体組成物 |
| CN113274494B (zh) * | 2021-06-07 | 2022-09-20 | 武汉生物制品研究所有限责任公司 | 一种抗SARS-CoV-2的重组全人源单克隆抗体的液体制剂 |
| CN115327130A (zh) * | 2022-07-25 | 2022-11-11 | 深圳市妇幼保健院 | 一种免疫生物标志物在制备小儿脓毒血症诊断试剂盒中的应用 |
| CN115724975A (zh) * | 2022-10-20 | 2023-03-03 | 江苏荃信生物医药股份有限公司 | 抗人白介素36受体单克隆抗体及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130236471A1 (en) * | 2011-11-16 | 2013-09-12 | Boehringer Ingelheim Gmbh | Anti il-36r antibodies |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| CA2635352C (en) | 1997-06-13 | 2012-09-11 | Genentech, Inc. | Stabilized antibody formulation |
| EP1003861B1 (en) | 1997-08-01 | 2006-10-04 | Schering Corporation | Mammalian cell membrane proteins; related reagents |
| US6416973B1 (en) | 1997-08-01 | 2002-07-09 | Schering Corporation | Nucleic acids encoding mammalian cell membrane protein MDL-1 |
| DE19733389C2 (de) | 1997-08-01 | 1999-08-19 | Deutsches Krebsforsch | Mittel zur Expression und zum Nachweis eines ein HPOL-Epitop und ein Polypeptid enthaltenden Fusionspolypeptids |
| JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
| EP1627927A3 (en) | 2001-03-01 | 2006-06-07 | Epigenomics AG | Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA |
| AU2003282667A1 (en) | 2002-10-03 | 2004-04-23 | Large Scale Biology Corporation | Multimeric protein engineering |
| MXPA05010555A (es) | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CN101389769A (zh) | 2005-12-28 | 2009-03-18 | 森托科尔公司 | 用于评价和治疗银屑病及相关疾病的标记与方法 |
| WO2008033333A2 (en) | 2006-09-08 | 2008-03-20 | Amgen Inc. | Il-1 family variants |
| WO2008133857A1 (en) | 2007-04-23 | 2008-11-06 | Schering Corporation | Anti-mdl-1 antibodies |
| ES2540854T3 (es) | 2007-06-29 | 2015-07-14 | Merck Sharp & Dohme Corp. | Usos de antagonistas MDL-1 |
| WO2009040602A1 (en) | 2007-09-25 | 2009-04-02 | Becton Dickinson France | Autoinject0r with deactivating means moveable by a safety shield |
| CA2701717C (en) | 2007-10-06 | 2016-11-29 | Arbitron, Inc. | Gathering research data |
| KR20110048536A (ko) | 2008-08-28 | 2011-05-11 | 와이어쓰 엘엘씨 | 자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도 |
| EP2458990B1 (en) | 2009-07-28 | 2016-03-30 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| LT2805731T (lt) | 2009-09-03 | 2019-02-11 | Ablynx N.V. | Stabilios polipeptidų kompozicijos ir jų panaudojimas |
| EP2575884B1 (en) | 2010-06-03 | 2018-07-18 | AbbVie Biotechnology Ltd | Uses and compositions for treatment of hidradenitis suppurativa (hs) |
| KR102063028B1 (ko) | 2012-01-23 | 2020-01-07 | 리제너론 파아마슈티컬스, 인크. | 항-ａｎｇ2 항체를 함유하는 안정화된 제형 |
| CH705992A2 (de) | 2012-10-11 | 2013-06-14 | Tecpharma Licensing Ag | Injektionsvorrichtung. |
| WO2015022656A1 (en) | 2013-08-15 | 2015-02-19 | Novartis Ag | Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists |
| CN105330740B (zh) | 2014-07-30 | 2018-08-17 | 珠海市丽珠单抗生物技术有限公司 | 抗pd-1抗体及其应用 |
| EP3194583B1 (en) | 2014-07-30 | 2021-09-15 | Zumutor Biologics, Inc. | Non-fucosylated protein and methods thereof |
| CA2874083C (en) | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| CN115925932A (zh) | 2015-04-15 | 2023-04-07 | 安奈普泰斯生物有限公司 | 针对白细胞介素36受体（il-36r）的抗体 |
| CN112870489B (zh) | 2015-04-24 | 2022-12-06 | 艾斯曲尔医疗公司 | 药剂输送装置的子组件和药剂输送装置 |
| CH711066A2 (de) | 2015-05-13 | 2016-11-15 | Tecpharma Licensing Ag | Verbesserte Injektionsvorrichtung. |
| CN106470162B (zh) | 2015-08-19 | 2019-06-25 | 中国移动通信集团公司 | 一种业务报文的组播方法及装置 |
| JP6654773B2 (ja) | 2015-12-25 | 2020-02-26 | 国立大学法人名古屋大学 | インターロイキン３６受容体アンタゴニスト欠損症の治療薬 |
| CN115400220A (zh) | 2015-12-30 | 2022-11-29 | 豪夫迈·罗氏有限公司 | 减少聚山梨酯降解的制剂 |
| JP2020512344A (ja) | 2017-03-27 | 2020-04-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗ｉｌ−３６ｒ抗体併用治療 |
| CN107362351B (zh) | 2017-09-04 | 2020-11-10 | 上海市儿童医院 | Il-36r的拮抗剂在制备镇痛药物中的应用 |
| JP2021517577A (ja) | 2018-03-14 | 2021-07-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 炎症性腸疾患の処置のための抗ｉｌ−３６ｒ抗体の使用 |
| BR112020016738A2 (pt) | 2018-03-14 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Uso de anticorpos anti-il-36r para o tratamento de psoríase pustular generalizada |
| AU2019306217B2 (en) | 2018-07-16 | 2024-01-25 | Regeneron Pharmaceuticals, Inc. | Anti-IL36R antibodies |
| HRP20240999T1 (hr) | 2018-07-16 | 2024-10-25 | Regeneron Pharmaceuticals, Inc. | Glodavački modeli bolesti ditra i njihova upotreba |
| TW202037604A (zh) | 2018-12-27 | 2020-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 治療掌蹠膿疱症之抗il-36r抗體 |
| IL286100B2 (en) | 2019-03-08 | 2024-12-01 | Boehringer Ingelheim Int | Anti-il-36r antibody formulations |
| KR102708558B1 (ko) | 2019-06-20 | 2024-09-24 | 삼성전자주식회사 | 수직형 메모리 장치 |
| CN115427439A (zh) | 2019-10-30 | 2022-12-02 | 德克萨斯A&M大学系统 | 用于双靶标嵌合抗原受体t细胞疗法的蛋白酶开关 |
| BR112022026999A2 (pt) | 2020-07-17 | 2023-01-24 | Boehringer Ingelheim Int | Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas |
| EP4221839A1 (en) | 2020-09-30 | 2023-08-09 | Boehringer Ingelheim International GmbH | Anti-il-36r antibodies for treatment of chronic inflammatory pain |
-
2019
- 2019-03-08 BR BR112020016738-0A patent/BR112020016738A2/pt unknown
- 2019-03-08 CA CA3093692A patent/CA3093692A1/en active Pending
- 2019-03-08 US US16/296,825 patent/US20190284285A1/en not_active Abandoned
- 2019-03-08 AU AU2019236105A patent/AU2019236105B2/en active Active
- 2019-03-08 CN CN201980019232.2A patent/CN112272674A/zh active Pending
- 2019-03-08 JP JP2020547406A patent/JP7404256B2/ja active Active
- 2019-03-08 KR KR1020207029378A patent/KR102768040B1/ko active Active
- 2019-03-08 MX MX2020009544A patent/MX2020009544A/es unknown
- 2019-03-08 WO PCT/US2019/021335 patent/WO2019177888A1/en not_active Ceased
- 2019-03-08 IL IL277215A patent/IL277215B2/en unknown
- 2019-03-08 EP EP19713267.3A patent/EP3765513A1/en active Pending
-
2020
- 2020-09-10 CL CL2020002342A patent/CL2020002342A1/es unknown
- 2020-09-11 PH PH12020551444A patent/PH12020551444A1/en unknown
- 2020-11-23 US US17/101,126 patent/US12503512B2/en active Active
-
2023
- 2023-12-13 JP JP2023209816A patent/JP7673168B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130236471A1 (en) * | 2011-11-16 | 2013-09-12 | Boehringer Ingelheim Gmbh | Anti il-36r antibodies |
Also Published As
| Publication number | Publication date |
|---|---|
| IL277215B1 (en) | 2025-06-01 |
| JP2024028951A (ja) | 2024-03-05 |
| CA3093692A1 (en) | 2019-09-19 |
| AU2019236105A1 (en) | 2020-08-27 |
| JP7404256B2 (ja) | 2023-12-25 |
| MX2020009544A (es) | 2020-10-05 |
| KR20200131871A (ko) | 2020-11-24 |
| CN112272674A (zh) | 2021-01-26 |
| IL277215A (en) | 2020-10-29 |
| EP3765513A1 (en) | 2021-01-20 |
| WO2019177888A1 (en) | 2019-09-19 |
| JP2021517566A (ja) | 2021-07-26 |
| PH12020551444A1 (en) | 2021-08-23 |
| JP7673168B2 (ja) | 2025-05-08 |
| CL2020002342A1 (es) | 2020-12-18 |
| US12503512B2 (en) | 2025-12-23 |
| AU2019236105B2 (en) | 2025-07-31 |
| US20190284285A1 (en) | 2019-09-19 |
| US20210087285A1 (en) | 2021-03-25 |
| KR102768040B1 (ko) | 2025-02-17 |
| BR112020016738A2 (pt) | 2020-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277215B2 (en) | Use of anti-IL-36R antibodies for the treatment of generalized pustular psoriasis | |
| JP2021517566A5 (https=) | ||
| JP2020002171A5 (https=) | ||
| JP2022512920A5 (https=) | ||
| RU2019106804A (ru) | Лечение и устойчивая вирусологическая ремиссия при вич-инфекции у haart-стабилизированных пациентов с помощью антител против cd4 | |
| JP2018508483A5 (https=) | ||
| RU2012137498A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| RU2017101705A (ru) | Фармацевтическая композиция, предназначенная для применения для предупреждения и/или лечения заболевания, которое развивается или прогрессирует вследствие снижения или утраты активности фактора свертывания крови viii и/или активированного фактора свертывания крови viii | |
| AR085281A1 (es) | Moduladores de la proteina tirosina quinasa 7 (ptk7) y metodos para su uso | |
| JP2016529255A5 (https=) | ||
| RU2020115713A (ru) | Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения | |
| JP2019531259A5 (https=) | ||
| PE20221585A1 (es) | Anticuerpo anti antigeno-4 asociado al linfocito t citotoxico (ctla-4) y uso del mismo | |
| PE20220487A1 (es) | Anticuerpos anti-ms4a4a y metodos de uso de los mismos | |
| JP2018529661A5 (https=) | ||
| MX2024014979A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer | |
| ZA202406651B (en) | Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and chiauranib | |
| IL314896A (en) | Methods of use of anti-trem2 antibodies | |
| MX2025003298A (es) | Anticuerpo anti-il-1r3 humanizado y metodos de uso | |
| AR095076A1 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| RU2020111574A (ru) | Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом | |
| RU2017112967A (ru) | Лечение и функциональное излучение вич-инфекции моноклональными антителами к cd4, опосредующими конкуретное ингибирование входа вич | |
| JP2026062640A5 (https=) | ||
| JP2009538916A5 (https=) | ||
| RU2020117362A (ru) | Способы лечения тендинопатии с помощью антагонистов интерлейкина-17 (il-17) |